Cargando…
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to evaluate antibody responses in individuals vaccina...
Autores principales: | Chansaenroj, Jira, Suntronwong, Nungruthai, Kanokudom, Sitthichai, Assawakosri, Suvichada, Yorsaeng, Ritthideach, Vichaiwattana, Preeyaporn, Klinfueng, Sirapa, Wongsrisang, Lakana, Srimuan, Donchida, Thatsanatorn, Thaksaporn, Thongmee, Thanunrat, Auphimai, Chompoonut, Nilyanimit, Pornjarim, Wanlapakorn, Nasamon, Sudhinaraset, Natthinee, Poovorawan, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317843/ https://www.ncbi.nlm.nih.gov/pubmed/35891235 http://dx.doi.org/10.3390/vaccines10071071 |
Ejemplares similares
-
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022) -
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022) -
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022) -
BBIBP-CorV: Hepatitis: case report
Publicado: (2022) -
BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)